A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 255 participants.
Also called NCT05687890
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 255 participants
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
- Registry
-
NCT05687890
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05687890. Randomized; double masking; primary purpose treatment. Start 2023-05-23 (actual); primary completion 2024-11-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
- Condition
- Diabetic Kidney Disease
- Condition
- IgA Nephropathy
- Intervention (Drug)
- Placebo of SC0062
- Intervention (Drug)
- SC0062 low dose
- Intervention (Drug)
- SC0062 medium dose
- Intervention (Drug)
- SC0062 high dose
- Lead sponsor
- Biocity Biopharmaceutics Co., Ltd.
Record details
- Record id
cardio:ct-nct05687890- Content hash
a6f16ed3059355b1c84f80a14ac6a8c28353190faaa85cc3e3936fbfa4669760